{
  "Country": "DK",
  "PICOs": [
    {
      "Population": "Adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation, performance status 0-2, who have progressed after at least one prior systemic therapy including platinum-based chemotherapy and immunotherapy (where applicable)",
      "Intervention": "2nd or 3rd line treatment with targeted therapy options for KRAS G12C mutation",
      "Comparator": "Standard chemotherapy or other targeted therapies not specific to KRAS G12C",
      "Outcomes": "Improvement in progression-free survival (PFS) and overall response rate (ORR)"
    }
  ],
  "SourceType": "clinical_guideline"
}